Skip to main content

Year: 2020

Final approval of the 3.4 billion loan package by the Dutch state

Roissy, 6 November 2020Final approval of the 3.4 billion loan package by the Dutch stateKLM is in the midst of the worst crisis in its 101-year history, with the COVID-19 pandemic eroding its strong performance of recent years. The EUR 3.4 billion loan package, consisting of a government loan and guarantees on bank loans, is crucial to securing the future of the airline and its network for the Netherlands. KLM is very grateful to the Dutch government for its support and willingness to provide financing at this time.The Dutch Government has made its loan package contingent on certain conditions, one being that all KLM employees must agree to adjust certain employment conditions for the duration of the loan (expected until 2025). KLM has spent the past few months hammering out the details of this austerity program with the trade unions...

Continue reading

Approbation finale de l’ensemble de prêts de 3,4 milliards par l’État néerlandais

Roissy, 6 Novembre 2020Approbation finale de l’ensemble de prêts de 3,4 milliards par l’État néerlandaisKLM traverse la pire crise de ses 101 années d’existence, la pandémie COVID-19 ayant érodé les bonnes performances de ces dernières années. L’enveloppe de 3,4 milliards d’euros, composée d’un prêt du gouvernement et de garanties sur des prêts bancaires, est cruciale pour garantir l’avenir de la compagnie aérienne et de son réseau aux Pays-Bas. KLM est très reconnaissante au gouvernement néerlandais pour son soutien et sa volonté de lui accorder un financement en cette période.Le gouvernement néerlandais a subordonné son ensemble de prêts à certaines conditions, l’une d’entre elles étant que tous les employés de KLM acceptent d’ajuster certaines conditions d’emploi pendant la durée...

Continue reading

AKVA group ASA: 3Q 2020 financial reporting

Solid quarter for the Cage Based business – total Group EBITDA of 105 MNOK in Q3 AKVA group delivered revenue for Q3 of 806 MNOK (771 MNOK), an increase of 4% compared to Q3 2019. EBITDA decreased from 115 MNOK in Q3 2019 to 105 MNOK in Q3 2020. The Net Profit decreased from 42 MNOK last year to 36 MNOK in Q3 2020. A net gain of 18 MNOK from the sale of Wise lausnir ehf was included in the 2019 revenue, EBITDA and net profit.The order intake in the quarter was 647 MNOK with a backlog of 1.63 BNOK at the end of September 2020. AKVA group have signed engineering and design contracts for full grow-out facilities in the quarter.AKVA group have decided to conduct a strategic review of AKVA Marine Services.The COVID-19 pandemic has had limited impact on AKVA group in the quarter.AKVA group have remained focused on the implemented measures started...

Continue reading

Financial reporting calendar for year 2021

In 2021 AS Ekspress Grupp will publish its consolidated financial results according to the schedule below.Reports will be published before the start of the trading day, at 8.00 a.m. local Eastern European time (EET).Shareholders general meeting for 2020 financial year will take place in 2nd quarter 2021, exact time and location will be confirmed accordingly.Signe KukinGroup CFOAS Ekspress GruppPhone: +372 669 8381E-mail: signe.kukin@egrupp.eeAS Ekspress Grupp is the leading media group in the Baltic States whose key activities include web media content production, publishing of newspapers and magazines and provision of printing services in Estonia, Latvia and Lithuania. The Group also manages the electronic ticket sales platform and ticket sales sites in Latvia. Ekspress Grupp that launched its operations in 1989 employs almost 1700 people,...

Continue reading

Finantskalender 2021. aastal

2021. aastal avaldab AS Ekspress Grupp konsolideeritud majandustulemused järgmiselt.Aruanded avalikustatakse enne börsipäeva algust kell 8.00 hommikul kohaliku Ida-Euroopa aja järgi (EET). 2020. majandusaasta aktsionäride korraline üldkoosolek toimub II kvartalis 2021, täpne aeg ja asukoht täpsustatakse edaspidi.Signe KukinKontserni finantsjuhtAS Ekspress GruppTel: +372 669 8381E-kiri: signe.kukin@egrupp.eeAS Ekspress Grupp on Baltimaade juhtiv meediakontsern, mille tegevus hõlmab veebimeedia sisutootmist, ajalehtede ja ajakirjade kirjastamist ning trükiteenuste osutamist Eestis, Lätis ja Leedus. Samuti haldab kontsern elektroonilist piletimüügiplatvormi ja piletimüügikohtasid Lätis. Ekspress Grupp, mis alustas oma tegevust 1989. aastal, annab tööd ligi 1700 inimesele, omab Baltimaades juhtivaid online-meedia portaale, annab välja kõige...

Continue reading

IDEX Biometrics to Participate at the ROTH Technology Virtual Event

Oslo, Norway, 6 November 2020:  IDEX Biometrics ASA, a leading provider of advanced fingerprint identification and authentication solutions, will be participating at the following virtual investor conference:ROTH Technology Virtual Event Conference 2020Dates: 11-12 November 2020IDEX will be represented by CEO Vince Graziani and CFO Derek D’Antilio. Any supporting presentation materials will be available on the date of the event in the Investors section of the company’s website at www.idexbiometrics.com.For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: + 47 918 00186Derek D’Antilio, Chief Financial OfficerE-mail: derek.dantilio@idexbiometrics.comTel: +1 978 273 1344About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX and OTCQB: IDXAF) is a leading provider of fingerprint identification...

Continue reading

Netcompany – Interim report for the nine months ended 30 September 2020

Company announcementNo. 19/202006 November 2020Netcompany continues to grow revenue and increases margins in Q3 2020In Q3 2020, Netcompany grew revenue in constant currencies to DKK 699.1m – 18.1% compared to the same period last year. In reported currencies revenue grew 17.3%.Adjusted EBITA grew 19.1% to DKK 195.5m compared to DKK 164.1m in Q3 2019, corresponding to an adjusted EBITA margin of 28.1%.Average number of full-time employees grew 482 from 2,345 in Q3 2019 to 2,827 in Q3 2020, corresponding to a growth of 20.5% – all organic.Free cash flow remained strong and improved by 18.5% from DKK 126.5m in Q3 2019 to DKK 149.9m in Q3 2020. As a consequence of the strong cash flow Netcompany reduced bank debt by DKK 200m in Q3 2020.Based on current expectations for full year performance, Netcompany expects to redistribute around...

Continue reading

UPDATE – Ceridian Reports Third Quarter 2020 Results

MINNEAPOLIS and TORONTO, Nov. 06, 2020 (GLOBE NEWSWIRE) — Please replace the release to the following corrected version due to multiple revisions.  The corrected release follows:Dayforce recurring services revenue of $122.7 million, up 12.2% year-over-year, both on a GAAP and a constant currency basis.Excluding float revenue, Dayforce recurring services revenue of $115.1 million, up 17.9% year-over-year, both on a GAAP and a constant currency basis.Dayforce revenue of $157.8 million, up 9.8% year-over-year, both on a GAAP and a constant currency basis.Excluding float revenue, Dayforce revenue of $150.2 million, up 13.9% year-over-year, both on a GAAP and a constant currency basis.  Cloud recurring services gross margin of 70.4%, an increase of 20 basis points year-over-year, and excluding float revenue, Cloud recurring service gross...

Continue reading

Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia

National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s partner CR GosunBasilea will receive CHF 3 million milestone payment from CR GosunBasel, Switzerland, November 06, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its license partner Shenzhen China Resources Gosun Pharmaceuticals Co. Ltd. (CR Gosun) has received a Drug Approval License from the National Medical Products Administration (NMPA) in China for Basilea’s antibiotic Zevtera® (ceftobiprole). With the Drug Approval License Authorization, Zevtera is now approved in China for the treatment of adult patients with community-acquired pneumonia (CAP) and adult patients with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). The granting of the Drug Approval License triggered a milestone payment of...

Continue reading

Basilea gibt Zulassung von Antibiotikum Zevtera® in China zur Behandlung von ambulant und im Spital erworbener Lungenentzündung bekannt

National Medical Products Administration (NMPA) erteilt Basileas Partner CR Gosun eine Drug Approval LicenseBasilea erhält CHF 3 Mio. Meilensteinzahlung von CR GosunBasel, 06. November 2020Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Lizenzpartner Shenzhen China Resources Gosun Pharmaceuticals Co. Ltd. (CR Gosun) von der National Medical Product Administration (NMPA) in China die Zulassung (Drug Approval License) für Basileas Antibiotikum Zevtera® (Ceftobiprol) erhalten hat. Damit ist Zevtera in China für die Behandlung von erwachsenen Patienten mit ambulant erworbener Lungenentzündung (engl. CAP) zugelassen, sowie für die Behandlung von erwachsenen Patienten mit im Spital erworbener Lungenentzündung (engl. HAP), mit Ausnahme der beatmungsassoziierten Pneumonie (engl. VAP). Die Erteilung der Drug Approval License löst...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.